Commercial Insight: Targeted Therapy Cancer Brands - High growth market will see eight new blockbusters by 2017 : Market Research Report

Commercial Insight: Targeted Therapy Cancer Brands - High growth market will see eight new blockbusters by 2017

Published by: Datamonitor

Published: Jul. 18, 2008 - 272 Pages

CHAPTER 1 EXECUTIVE SUMMARY: Strategic scoping and focus; Datamonitor insight into the targeted therapy cancer brands market; Related reports; Upcoming reports
CHAPTER 2 MARKET DEFINITION: Definition of the cancer market by ATC class; Molecular targeted therapies; L1X3 - Antineoplastic monoclonal antibodies; L1X9 - All other antineoplastics
CHAPTER 3 MARKET OVERVIEW AND FORECASTS: Seven major markets; Current market assessment; Sales by class; Sales by brand; Sales by country; Future market assessment; Sales by class; Sales by brand; Sales by country; Opportunities and threats; US; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; Japan; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; 5EU; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; France; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; Germany; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; Italy; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; Spain; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; UK; Current market assessment; Sales by class; Sales by brand; Future market assessment; Sales by class; Sales by brand; Rest of World snapshot; Current market assessment; Global monoclonal antibody brand market; Global small molecule brand market
CHAPTER 4 BRAND DYNAMICS: Brand analysis by class; Seven major markets; Analysis of current market; Analysis of future market; US; Analysis of current market; Analysis of future market; Japan; Analysis of current market; Analysis of future market; 5EU; Analysis of current market; Analysis of future market; France; Analysis of current market; Analysis of future market; Germany; Analysis of current market; Analysis of future market; Italy; Analysis of current market; Analysis of future market; Spain; Analysis of current market; Analysis of future market; UK; Analysis of current market; Analysis of future market; Brand analysis by approval date; Since 2005, 10 new targeted therapies have reached the market; Brand analysis by indication; Solid tumors versus hematological malignancies; Targeted therapy cancer brands approved for solid tumors had the highest market share and showed the largest growth in 2007; Targeted therapy cancer brands approved for solid tumors will gain even more market share by 2017; Analysis of brand by number of approved indications; Avastin is the leading targeted therapy cancer brand in terms of the number of approved indications; Analysis of indication by number of approved targeted therapies; Non-Hodgkin’s lymphoma is the indication with the most approved targeted therapy cancer brands; Brand analysis by mode of administration; Intravenously administered targeted therapy cancer brands have the greatest market share; Brand analysis by company; 23 different companies are involved in the marketing of targeted therapy cancer brands in the seven major markets; Co-marketed targeted therapy cancer brands have the largest market share in 2007; Brand analysis by event; Avastin will experience the greatest number of forecast events across the seven major markets
CHAPTER 5 BRAND PROFILES AND FORECASTS: Avastin; Brand profile; Brand forecast events; Brand forecast to 2017; Avastin set to become the biggest-selling targeted therapy cancer brand in the seven major markets in 2009; Bexxar; Brand profile; Brand forecast events; Brand forecast to 2017; Campath; Brand profile; Brand forecast events; Brand forecast to 2017; Erbitux; Brand profile; Brand forecast events; Brand forecast to 2017; Erbitux seven major market sales passed $1 billion in 2007 and are set for modest growth through line extensions and new approvals; Gleevec; Brand profile; Brand forecast events; Brand forecast to 2017; Patent expiries across the seven major markets will curb long-term growth of Gleevec sales; Herceptin; Brand profile; Brand forecast events; Brand forecast to 2017; Herceptin well placed to maintain strong performance in breast cancer market; Iressa; Brand profile; Brand forecast events; Brand forecast to 2017; Iressa’s declining sales could experience a turnaround following new Phase III lung cancer trial; Mylotarg; Brand profile; Brand forecast events; Brand forecast to 2017; Nexavar; Brand profile; Brand forecast events; Brand forecast to 2017; Liver cancer approval will help Nexavar to make up for disappointing performance in RCC market; Ontak; Brand profile; Brand forecast events; Brand forecast to 2017; Revlimid; Brand profile; Brand forecast events; Brand forecast to 2017; First-line multiple myeloma approval will allow Revlimid to reach sales of $1 billion in the seven major markets by 2015; Rituxan; Brand profile; Brand forecast events; Brand forecast to 2017; Rituxan was the biggest-selling targeted therapy cancer brand in 2007; Sprycel; Brand profile; Brand forecast events; Brand forecast to 2017; Generic imatinib and competition from Tasigna will limit Sprycel’s uptake in first-line CML; Sutent; Brand profile; Brand forecast events; Brand forecast to 2017; Indication expansion will enable Sutent to become the leading small molecule targeted therapy cancer brand in 2017; Tarceva; Brand profile; Brand forecast events; Brand forecast to 2017; Additional lung cancer approvals will help drive growth of Tarceva sales; Targretin; Brand profile; Brand forecast events; Brand forecast to 2017; Tasigna; Brand profile; Brand forecast events; Brand forecast to 2017; Tasigna is well-positioned to compensate for Gleevec patent expiry; Thalomid; Brand profile; Brand forecast events; Brand forecast to 2017; Torisel; Brand profile; Brand forecast events; Brand forecast to 2017; Tykerb; Brand profile; Brand forecast events; Brand forecast to 2017; Breast cancer line extensions will push Tykerb sales beyond $1.4 billion in the seven major markets by 2017; Vectibix; Brand profile; Brand forecast events; Brand forecast to 2017; Vectibix is set to lag behind Erbitux and Avastin in the colorectal cancer market; Velcade; Brand profile; Brand forecast events; Brand forecast to 2017; Velcade seven major market sales will reach $1 billion by 2010 following approval for first-line multiple myeloma; Zevalin; Brand profile; Brand forecast events; Brand forecast to 2017; Zolinza; Brand profile; Brand forecast events; Brand forecast to 2017
APPENDIX A - MARKET ASSUMPTIONS: Country-specific assumptions and events; Effect of Medicare Modernization Act in the US; Biennial price cuts in Japan; Generic erosion assumptions; Data definitions, limitations and assumptions; Standard units; Japanese market data; Derivation of sales forecasts and pricing trends; Forecasts; Forecast methodology
APPENDIX B: Bibliography; List of figures; Abbreviations; Report methodology; About Datamonitor; About Datamonitor Healthcare; Disclaimer

Abstract

Introduction

Targeted therapies are the top selling class of cancer drug, reaching sales of nearly $15 billion in the seven major pharmaceutical markets in 2007. The high growth of this therapy class makes it attractive to drug developers, resulting in 10 new entrants to the market since 2005. More drugs are likely to gain approval in the near future, contributing to a rapidly changing competitive landscape.

Scope

Forecast sales of every marketed targeted therapy cancer brand in each of the seven major markets over the period 2007 to 2017
Analysis and segmentation of the market at various levels including drug class, indication, company and mode of administration
Comprehensive brand profiles and analysis, including approval dates, patent expiries and all key events likely to impact sales
Snapshot of the targeted therapy cancer brands market in the rest of the world

Highlights

The targeted therapy cancer brands market is rapidly expanding and is forecast to maintain a high growth rate over the forecast period. The market will reach a value of over $42 billion by 2017 in the seven major pharmaceutical markets, growing at a CAGR of 11%

Approvals in new tumor types with high unmet need, use in earlier treatment settings and growing physician familiarity are among the factors likely to drive sales of the best performing targeted therapy brands. However, pharmacoeconomic pressures and the launch of generic and pipeline competitors will dampen the growth of certain brands

Monoclonal antibody targeted therapy cancer brands achieved higher sales than small molecule agents in 2007 and will remain the leading class over the forecast period. This is driven by the considerable success of the monoclonal antibody brands Avastin, Herceptin and Rituxan

Reasons to Purchase

Quantify the performance of each of the marketed targeted therapy cancer brands in the seven major markets over the period 2007 to 2017
Assess the changing key opportunities and threats both for currently marketed and pipeline targeted therapy cancer brands
Identify the leading brands in this market over the next 10 years and understand the key factors driving their success

Please note: This is delivered as a Zip file.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Commercial Insight: Targeted Therapy Cancer Brands - High growth market will see eight new blockbusters by 2017

Table of Contents

Abstract